Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2008-10-8
pubmed:databankReference
pubmed:abstractText
This study tested whether donor-derived HIV-specific immune responses could be detected when viral replication was completely suppressed by the continuous administration of highly active antiretroviral therapy (HAART). A regimen of fludarabine and 200 cGy total body irradiation was followed by infusion of allogeneic donor peripheral blood cells and posttransplantation cyclosporine and mycophenolate mofetil. Viral load, lymphocyte counts, and HIV-1-specific CD8(+) cell immune responses were compared before and after hematopoietic cell transplantation (HCT). Uninterrupted administration of HAART was feasible during nonmyeloablative conditioning and after HCT. The HIV RNA remained undetectable and no HIV-associated infections were observed. CD8(+) T-cell responses targeting multiple epitopes were detected before HCT. After HCT a different pattern of donor-derived HIV-specific CTL responses emerged by day +80, presumably primed in vivo. We conclude that allogeneic HCT offers the unique ability to characterize de novo HIV-1-specific immune responses. This clinical trial was registered at ClinicalTrials.gov (identifier: NCT00112593).
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-10357375, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-11781257, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-12791654, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-15021321, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-15388574, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-16545729, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-17329344, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-17620824, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-18008230, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-1975487, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-2059380, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-2403756, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-3111037, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-3165981, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-3278751, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-6131294, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-8308102, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-8898752, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-8971396, http://linkedlifedata.com/resource/pubmed/commentcorrection/18698002-9433423
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1528-0020
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
112
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3484-7
pubmed:dateRevised
2010-9-21
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation.
pubmed:affiliation
Fred Hutchinson Cancer Research Center, Seattle, WA, USA. awoolfre@fhcrc.org
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, N.I.H., Extramural